Literature DB >> 15339969

Probabilities of death from breast cancer and other causes among female breast cancer patients.

Catherine Schairer1, Pamela J Mink, Leslie Carroll, Susan S Devesa.   

Abstract

BACKGROUND: Among cancer patients, probabilities of death from that cancer and other causes in the presence of competing risks are optimal measures of prognosis and of mortality across demographic groups. We used data on breast cancer patients from the Surveillance, Epidemiology, and End Results (SEER) Program in a competing-risk analysis.
METHODS: We determined vital status and cause of death for 395,251 white and 35,259 black female patients with breast cancer diagnosed from January 1, 1973, through December 31, 2000, by use of SEER data. We calculated probabilities of death from breast cancer and other causes according to stage, race, and age at diagnosis; for cases diagnosed from January 1, 1990, to December 31, 2000, we also calculated some such probabilities according to tumor size and estrogen receptor (ER) status. All statistical tests were two-sided.
RESULTS: The probability of death from breast cancer after nearly 28 years of follow-up ranged from 0.03 to 0.10 for patients with in situ disease to 0.70 to 0.85 for patients with distant disease, depending on race and age. The probability of death from breast cancer at the end of the follow-up period generally declined with age at diagnosis; the probability among the oldest (> or =70 years) compared with the youngest (<50 years) patients was 33% lower for white and 46% lower for black patients with localized disease and 14% lower for white patients and 13% lower for black patients with distant disease. The probability of death from breast cancer exceeded that from all other causes for patients diagnosed with localized disease before age 50 years, with regional disease before age 60 years, and with distant disease at any age. The probability of death from breast cancer for patients diagnosed with localized or regional disease was statistically significantly greater in black patients than in white patients (all six P values < or =.01 for age groups 30-49 to 60-69 years; two P values < or =.04 for ages > or =70 years). Among patients with localized or regional disease and known ER status, the probability of death from breast cancer after nearly 11 years of follow-up ranged from 0.04 to 0.11 for patients with localized ER-positive tumors of 2 cm or less to 0.37 to 0.53 for patients with regional ER-negative tumors.
CONCLUSIONS: The probability of death from breast cancer versus other causes varied substantially according to stage, tumor size, ER status, and age at diagnosis in both white and black patients.

Entities:  

Mesh:

Year:  2004        PMID: 15339969     DOI: 10.1093/jnci/djh253

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  78 in total

Review 1.  Adjuvant chemotherapy for breast cancer in older women: emerging evidence to aid in decision making.

Authors:  Gretchen Kimmick
Journal:  Curr Treat Options Oncol       Date:  2011-09

2.  Correspondence (letter to the editor): No call for undertreatment.

Authors:  J Matthias Wenderlein
Journal:  Dtsch Arztebl Int       Date:  2012-01-27       Impact factor: 5.594

Review 3.  The interface between primary and oncology specialty care: treatment through survivorship.

Authors:  Eva Grunfeld; Craig C Earle
Journal:  J Natl Cancer Inst Monogr       Date:  2010

4.  Developing countries: an evolving opportunity for oncologic research.

Authors:  Rajendra A Badwe; Anil K D'cruz; Rajesh C Mistry; Hemant B Tongaonkar; Surendra Shastri; Mangesh A Thorat
Journal:  World J Surg       Date:  2006-07       Impact factor: 3.352

5.  Twenty-five years of breast cancer risk models and their applications.

Authors:  Mitchell H Gail
Journal:  J Natl Cancer Inst       Date:  2015-02-26       Impact factor: 13.506

Review 6.  Running on empty: cardiovascular reserve capacity and late effects of therapy in cancer survivorship.

Authors:  Graeme J Koelwyn; Michel Khouri; John R Mackey; Pamela S Douglas; Lee W Jones
Journal:  J Clin Oncol       Date:  2012-10-08       Impact factor: 44.544

Review 7.  Psychoneuroimmunology and cancer: a decade of discovery, paradigm shifts, and methodological innovations.

Authors:  Paige Green McDonald; Mary O'Connell; Susan K Lutgendorf
Journal:  Brain Behav Immun       Date:  2013-01-16       Impact factor: 7.217

8.  Genes that mediate breast cancer metastasis to lung.

Authors:  Andy J Minn; Gaorav P Gupta; Peter M Siegel; Paula D Bos; Weiping Shu; Dilip D Giri; Agnes Viale; Adam B Olshen; William L Gerald; Joan Massagué
Journal:  Nature       Date:  2005-07-28       Impact factor: 49.962

9.  DNA hypermethylation of ESR1 and PGR in breast cancer: pathologic and epidemiologic associations.

Authors:  Mia M Gaudet; Mihaela Campan; Jonine D Figueroa; Xiaohong R Yang; Jolanta Lissowska; Beata Peplonska; Louise A Brinton; David L Rimm; Peter W Laird; Montserrat Garcia-Closas; Mark E Sherman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-10-27       Impact factor: 4.254

10.  The multiplex bead array approach to identifying serum biomarkers associated with breast cancer.

Authors:  Byoung Kwon Kim; Jong Won Lee; Pil Je Park; Yong Sung Shin; Won Young Lee; Kyung Ae Lee; Sena Ye; Heesun Hyun; Kyung Nam Kang; Donghwa Yeo; Youngdai Kim; Sung Yup Ohn; Dong Young Noh; Chul Woo Kim
Journal:  Breast Cancer Res       Date:  2009-04-28       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.